Multiple sclerosis onset after granulocyte macrophage colony-stimulating factor withdrawal
| Autor: | M. Cohen, Emmanuelle Waubant, Janet Chong |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Multiple Sclerosis Antineoplastic Agents 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Stage III melanoma Melanoma business.industry Multiple sclerosis Brain Granulocyte-Macrophage Colony-Stimulating Factor General Medicine Middle Aged medicine.disease Recombinant Proteins Discontinuation Clinical trial 030104 developmental biology Granulocyte macrophage colony-stimulating factor Thigh Neurology Female Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Multiple Sclerosis and Related Disorders. 20:178-180 |
| ISSN: | 2211-0348 |
| DOI: | 10.1016/j.msard.2018.01.025 |
| Popis: | A 51-year old woman with stage III melanoma participated in a phase II clinical trial in which she received subcutaneous rhGM-CSF injections for 3 years. She was in remission by the end of the trial. Seven months after discontinuing GM-CSF she had her first MS event. The unique timeline of rh-GM-CSF injections in a melanoma trial, during which yearly MRI scans showed subtle stable demyelination followed by RRMS onset shortly after discontinuation of treatment, may provide some insight on the role of GM-CSF in MS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect